– Funds will enable launch of prenatal noninvasive genetic testing
Seattle, WA – June 4, 2021 – Zoic Capital, a venture firm focused on early-stage medical technology investments, announced that portfolio company Juno Diagnostics has closed its $25M Series A financing. The proceeds will be used to support the development and commercial launch of JunoDx’s noninvasive prenatal gender test.
According to Neal Mody, Managing Director at Zoic Capital, “JunoDx has the potential to transform the genetic testing industry. We are pleased that the company is now positioned to launch the first application of its revolutionary genetic testing platform.”
JunoDx’s prenatal test analyzes “cell-free DNA,” fetal DNA that circulates in the maternal bloodstream. The JunoDx platform simplifies sample collection and improves access to high-quality genetic testing results without the high cost, long lead times, and phlebotomy requirements of traditional tests.
“We are dedicated to bringing the most advanced and cost-effective NIPT solution to market in support of millions of families along their pregnancy journey,” said JunoDx CEO Dirk van den Boom.
About Zoic Capital
Zoic Capital is a venture firm based in Seattle, Washington that identifies, invests in, and fosters early-stage medical technology companies. For more information, visit www.zoiccapital.com.
About Juno Diagnostics
Juno Diagnostics is developing genetic testing solutions to improve access to vital health information. The Company’s lead product is a NIPT solution that simplifies sample collection and improves access to high-quality genetic testing results without the high cost, long lead times, and phlebotomy requirements of traditional NIPT. The founding team worked together at Sequenom, Inc., pioneering the development and commercialization of the first non-invasive cell-free DNA-based prenatal test in the United States. For more information, visit www.junodx.com.